What is Essential Thrombocythemia and Why Should You Care?

Published: Apr 22, 2024

Essential Thrombocythemia (ET) is a rare blood disorder that causes the body to produce too many platelets, which can lead to blood clots or bleeding. Learn how this condition affects the body and why it's important to know about it.

What Causes Essential Thrombocythemia?

Essential Thrombocythemia occurs when there is an overproduction of platelets due to changes in the bone marrow. These changes are often linked to genetic mutations in genes like JAK2, CALR, or MPL, which affect the blood cell production process. While the exact cause isn't fully understood, these mutations are a major factor in developing ET.

Who is at Risk?

ET can affect anyone, but it is more common in middle-aged and older adults, with a higher incidence in women. It's less common in children, but when it does occur, it appears to be relatively benign. Factors like race, sex, and age play a role in the likelihood of developing ET.

Essential Thrombocythemia (ET) is a rare blood disorder where the body produces too many platelets, leading to potential blood clots or bleeding. It is associated with genetic mutations in JAK2, CALR, or MPL genes.

Recognizing the Symptoms

Many people with ET don't have symptoms and discover the condition through a routine blood test. When symptoms do occur, they may include headaches, dizziness, or visual changes. Serious complications can involve blood clots or bleeding, making early detection vital.

Frequently Asked Questions

What is the main cause of ET? +

ET is mainly caused by genetic mutations in JAK2, CALR, or MPL genes.

Who is most at risk for ET? +

Middle-aged and older adults, particularly women, are most at risk.

What are common symptoms of ET? +

Common symptoms include headaches, dizziness, and visual changes.

Can ET be detected early? +

Yes, ET is often detected through routine blood tests before symptoms appear.

Key Takeaways

Understanding ET can help manage risks and improve health outcomes.

Talk with Doctronic today to learn more about your risk for ET.

References

Rumi E, Passamonti F, Della Porta MG, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007; 25:5630.

Rumi E, Harutyunyan AS, Pietra D, et al. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood 2014; 123:2416.

Always discuss health information with your healthcare provider.